US Patent 11,904,027: Scope, Claim Set, and US Landscape for 177Lu–DOTA Somatostatin Receptor Complex Formulations
US Patent 11,904,027 is directed to a manufacturing process and the resulting pharmaceutical aqueous solution for radiolabelled ¹⁷⁷Lu complexes where the radionuclide is bound to a somatostatin receptor binding peptide linked to DOTA, with explicit control of radiolysis stabilizers, dilution conditions, radionuclide concentration, and ethanol content. The claim set emphasizes stabilizer identity (e.g., gentisic acid and ascorbic acid), stabilizer ratio ranges, and a specific volumetric radioactivity window of 250 to 500 MBq/mL plus ethanol at <1%.
The claims cover both a process route that uses one stabilizer during complex formation and forces a different stabilizer into the dilution step, and embodiments where two stabilizers are present in the formulation system.
What does the invention claim, at the highest level?
The independent claim (Claim 1) and dependent claim family define a manufacturing workflow:
-
Provide a solution containing:
- a complex of ¹⁷⁷Lu (lutetium-177) and a somatostatin receptor binding peptide linked to DOTA,
- a first radiolysis stabilizer,
- and optionally a second radiolysis stabilizer different from the first.
-
Dilute the complex solution using an aqueous dilution solution that contains at least one stabilizer against radiolytic degradation.
-
Enforce conditional stabilizer placement:
- If the complex solution has only the first stabilizer (no second stabilizer), then the dilution solution must include at least one stabilizer that is different from the first stabilizer.
-
Constrain critical quantitative parameters in the resulting pharmaceutical aqueous solution:
- Volumetric radioactivity: 250 to 500 MBq/mL
- First stabilizer concentration: 0.5 to 2 mg/mL
- Stabilizer concentration ratio (between first and second): 1:3 to 1:7
- Ethanol: <1%
Claim 20 and Claim 23 then capture the pharmaceutical aqueous solution itself, with additional constraints on ethanol and stabilizer composition/total concentration and stability.
Key independent claim anchors
- Radionuclide + targeting + chelator: ¹⁷⁷Lu + somatostatin receptor binding peptide + DOTA
- Radiolysis stabilizers: at least one stabilizer system; ratio control between first and second
- Dilution rule: if complex has only one stabilizer, dilution must introduce a different stabilizer
- Product specs: 250–500 MBq/mL, first stabilizer 0.5–2 mg/mL, ethanol <1%
(Claims 1 and 22 are substantively similar but differ in the stabilizer ratio band.)
How is the claim set structured (independent vs dependent coverage)?
Independent claims
- Claim 1: Process + product parameter locks (including ethanol <1% and stabilizer ratio 1:3 to 1:7).
- Claim 2: Process elaboration with explicit complex formation steps (mixing aqueous solutions + heating) plus a dilution step rule (if only one stabilizer during complex formation, dilution introduces different stabilizer).
- Claim 20: Product claim for the pharmaceutical aqueous solution obtained by Claim 1.
- Claim 22: Alternate ratio band process (stabilizer ratio 1:4 to 1:5) plus ethanol <1%.
- Claim 23: Product claim for the pharmaceutical aqueous solution obtained by Claim 22.
Core dependent claims (mechanistic and parameter narrowing)
-
Complex formation and conditions:
- Formation route with aqueous Lu solution (Claim 2, including step 1.1),
- Peptide-chelator stabilizer solution (Claim 2, step 1.2),
- Mixing and heating to form the complex (Claim 2, step 1.3), including specific temperature and time windows (Claims 12–13).
-
Stabilizer identity examples:
- Gentisic acid (or salt) as first stabilizer, and ascorbic acid (or salt) in dilution (Claims 4–5).
- Two-step system where only gentisic acid during complex formation and only ascorbic acid in dilution (Claim 5).
-
Stabilizer concentrations:
- Total stabilizer during complex formation: 15 to 50 mg/mL (Claim 6)
- Narrower: 20 to 40 mg/mL (Claim 7)
- Gentisic acid only during complex formation: 20 to 40 mg/mL (Claim 8)
- Further narrow: 25 to 35 mg/mL (Claim 9)
-
Buffer identity:
- Buffer included in step 1.2 (Claim 10), specifically acetate buffer (Claim 11).
-
Optional chelators in dilution:
- Dilution step includes DTPA or salt (Claim 14)
-
Manufacturing downstream steps:
- 0.2 μm filtration (Claim 15)
- dispensing into dose unit containers to deliver 7.4 GBq ±10% (Claim 15)
- Container format: stoppered vials in a lead container (Claim 19)
-
Example reactant forms:
- Lu source as LuCl3 and HCl (Claim 16)
- Peptide complexes exemplified as ¹⁷⁷Lu-DOTA-TATE or ¹⁷⁷Lu-DOTA-TOC with gentisic acid, acetic acid, and sodium acetate (Claim 17)
- Dilution solution includes DTPA and ascorbic acid (Claim 18)
-
Product restrictions and stability:
- Product of Claim 20: ethanol-free (Claim 21)
- Product of Claim 22: ethanol <1% already; further embodiments:
- stabilizers consist essentially of gentisic acid and ascorbic acid (Claim 24)
- total stabilizers: 2.7 to 4.1 mg/mL (Claim 25)
- radiochemical purity by HPLC: ≥95% for at least 72 h at 25°C (Claim 26)
Alternate ratio band family (Claim 22 vs Claim 1)
- Claim 1: stabilizer ratio between first and second is 1:3 to 1:7
- Claim 22: stabilizer ratio between first and second is 1:4 to 1:5
This matters because a formulation that stays within one ratio band may still infringe the other depending on numerical overlap. The bands are close enough that process tuning becomes a central freedom-to-operate parameter.
What are the quantitative limits that drive infringement risk?
The claims contain several “hard numbers” that appear intended to be the main claim-differentiators.
Volumetric radioactivity window
- 250 to 500 MBq/mL in the final pharmaceutical aqueous solution (Claims 1 and 22)
Ethanol content
- <1% ethanol in the final pharmaceutical aqueous solution (Claims 1 and 22)
- Separate product claim: Claim 21 requires the product of Claim 20 to be free of ethanol
Stabilizer concentration ranges
- First stabilizer concentration:
- Total stabilizers during complex formation:
- 15 to 50 mg/mL (Claim 6)
- 20 to 40 mg/mL (Claim 7)
- Gentisic acid only:
- 20 to 40 mg/mL (Claim 8)
- 25 to 35 mg/mL (Claim 9)
Stabilizer ratio bands
- Claim 1:
- ratio between first and second stabilizers: 1:3 to 1:7
- Claim 22:
- ratio between first and second stabilizers: 1:4 to 1:5
Heat and time for complex formation
- Heating temperature:
- 70 to 99°C for 2 to 59 min (Claim 12)
- Narrower:
- 90 to 98°C for 5 to 15 min (Claim 13)
Dose delivery specification (manufacturing step)
- Dose unit containers configured for delivery of:
Downstream sterile preparation
- Filter through 0.2 μm (Claim 15)
Stability claim
- HPLC radiochemical purity maintained at:
- ≥95% for at least 72 h at 25°C (Claim 26)
How does the “stabilizer placement” rule work legally (and why it narrows workarounds)?
Both Claim 1 and Claim 2 contain the same logic:
- During formation of the ¹⁷⁷Lu–DOTA–somatostatin peptide complex:
- you have a first stabilizer, and a second is optional
- During dilution:
- the dilution solution has at least one stabilizer
- If the complex contains only the first stabilizer (no second stabilizer):
- then the dilution solution must include a stabilizer that is different from the first
That rule reduces common alternatives where a manufacturer might try to keep a single stabilizer throughout and then only adjust concentration rather than identity. The claims are explicit that identity must change between formation and dilution in the single-stabilizer formation case.
What stabilizer systems are explicitly taught?
Gentisic acid and ascorbic acid pairing (central embodiment)
- Claim 4: gentisic acid (or salt) in step (1.2), and ascorbic acid (or salt) in dilution step (2.1)
- Claim 5: only gentisic acid in complex formation and only ascorbic acid in dilution
Other formulation components exemplified
- Buffer: acetate buffer (Claims 10–11)
- Optional chelator in dilution: DTPA or salt (Claim 14), and in an example DTPA + ascorbic acid (Claim 18)
- Lu source: LuCl3 and HCl (Claim 16)
- Example peptide-complex + stabilizer in step (1.2):
- ¹⁷⁷Lu-DOTA-TATE or ¹⁷⁷Lu-DOTA-TOC plus gentisic acid, acetic acid, sodium acetate (Claim 17)
Does the patent claim the final product outside of a “process-by-product” structure?
Claim 20 and Claim 23 are direct product claims tied to the process results:
- Claim 20: “pharmaceutical aqueous solution obtained by the process of claim 1”
- Claim 21: Claim 20 ethanol-free
- Claim 23: “pharmaceutical aqueous solution obtained by the process of claim 22”
- Claims 24–26: product composition and stability in those resulting solutions
This is a product-by-result framing. In practice, it still creates product infringement pathways because the target product is defined by composition and performance (e.g., stabilizer composition “consists essentially of” and HPLC purity at 25°C).
What is the likely US patent landscape around these exact formulation elements?
A precise landscape requires the claims text to be cross-mapped against:
- prior art application filings covering ¹⁷⁷Lu–DOTA–peptide radiopharmaceutical formulation stabilizers,
- and later filings covering ethanol limits, stabilizer ratios, and dilution-step stabilizer switching.
However, based on the claim anatomy, the relevant “prior art clusters” are predictable:
1) Radiolysis stabilizers for ¹⁷⁷Lu-DOTA-peptide aqueous formulations
Common radiolysis mitigation approaches for Lu-177 peptide conjugates involve antioxidant systems and sometimes chelators. This patent explicitly focuses on:
- gentisic acid and ascorbic acid as a paired system,
- and DTPA as an additional component in the dilution solution.
2) Use of ethanol and its control
The claim line item “ethanol <1%” (and a separate ethanol-free embodiment) targets a measurable formulation attribute. Competitors using higher ethanol content would avoid this element, but competing formulations will often need ethanol for solubilization only if not otherwise addressed.
3) Two-stage stabilizer strategy (formation vs dilution)
The strongest legal differentiator is the rule that if only first stabilizer is present during complex formation, then the dilution solution must add a different stabilizer. This is narrower than “use antioxidants” and more specific than “adjust radiolysis stabilizer concentration.”
4) Dose-ready packaging steps tied to the formulation
Claim 15 adds a process pathway including 0.2 μm filtration and a packaging/dose delivery spec (7.4 GBq ±10%). Some product workflows may stop at vial filling with different target dose assumptions, which changes infringement risk.
5) Stability/performance via HPLC purity over time
Claim 26 uses an objective stability metric: HPLC purity ≥95% over 72 hours at 25°C. That can be used by challengers to argue lack of novelty if the same metric was already achieved, or by owners to distinguish prior art formulations that underperform.
Where are the strongest “design-around” pressure points? (Claim mapping lens)
Pressure point A: Ethanol constraint
- Any competitor formulation with ethanol ≥1% would fall outside Claims 1 and 22’s ethanol limit, but must still manage radiolysis in other claim-relevant ways.
Pressure point B: Stabilizer identity switching rule
- If complex formation includes only one stabilizer, the dilution step must include a different stabilizer. This blocks a simple “keep only one antioxidant everywhere” strategy.
Pressure point C: Stabilizer ratio bands
- Sliding the ratio outside the band can avoid infringement on those numerical elements:
- Claim 1 band: 1:3 to 1:7
- Claim 22 band: 1:4 to 1:5
Pressure point D: Final radioactivity concentration window
- The product must be at 250–500 MBq/mL. Different batch dilution targets could avoid.
Pressure point E: Temperature/time formation heating
- Claims 12–13 narrow to 90–98°C for 5–15 min, but Claim 1 and 2 can still be read more broadly via Claim 2 without the narrower dependent limitations unless those dependent claims are asserted.
What do the dependent claims add for enforceability and leverage?
Gentisic acid/ascorbic acid “consists only” embodiments
- Claims 4–5 lock the stabilizer pair to specific antioxidants, reducing ambiguity for infringement and strengthening the evidentiary pathway for composition-based enforcement.
Concentration targets (mg/mL)
- Claims 6–9 create a tight concentration envelope during formation. These are measurable, batch-specific, and typically validated by analytical methods.
Buffer and chelator specificity
- Acetate buffer (Claims 10–11)
- DTPA presence (Claims 14 and 18)
These elements are likely included to ensure operational consistency and to control radiochemical stability and free chelator exchange.
Performance claim (HPLC purity)
- Claim 26 gives an objective stability benchmark that can support enforcement where the final product meets the claimed performance despite changes in upstream steps, at least within the constraints of “obtained by” structure.
Key Takeaways
- US Patent 11,904,027 is centered on ¹⁷⁷Lu–DOTA–somatostatin peptide aqueous formulations with explicit radiolysis stabilizer control, ethanol limits (<1%), and a final volumetric radioactivity window (250–500 MBq/mL).
- The principal differentiator is a stabilizer placement rule: if complex formation uses only a first stabilizer, then dilution must add a different stabilizer.
- Enforcement leverage concentrates on quantitative parameters (MBq/mL, stabilizer mg/mL, stabilizer ratio bands) and measurable attributes (ethanol %, HPLC radiochemical purity over time).
- Dependent claims further narrow to gentisic acid/ascorbic acid, acetate buffer, DTPA, heat/time windows, and downstream steps (0.2 μm filtration and 7.4 GBq ±10% dose filling).
FAQs
1) What does the patent protect: a compound, a formulation, or a manufacturing method?
It protects both: (i) a manufacturing process for the radiolabelled aqueous solution and (ii) the pharmaceutical aqueous solution obtained by that process (Claims 1–2 and 20–23).
2) Which stabilizers are most central to the claim set?
The key explicit antioxidant system is gentisic acid (or salt) and ascorbic acid (or salt), with specific placement between complex formation and dilution (Claims 4–5).
3) What numerical limits most constrain product design?
The final product must have 250–500 MBq/mL, ethanol <1%, and (depending on which ratio-band claim applies) a first/second stabilizer ratio of 1:3 to 1:7 (Claim 1) or 1:4 to 1:5 (Claim 22).
4) Are there stability performance targets in the claims?
Yes. Claim 26 requires HPLC radiochemical purity ≥95% for at least 72 hours at 25°C.
5) Do the claims cover dose-ready manufacturing steps?
Yes. Claim 15 adds 0.2 μm filtration and dispensing into dose unit containers configured to deliver 7.4 GBq ±10%, with packaging exemplified as stoppered vials in a lead container (Claim 19).
References
[1] US Patent 11,904,027, “Process for manufacturing a pharmaceutical aqueous solution of ¹⁷⁷Lu complex with a somatostatin receptor binding peptide linked to DOTA and stabilizers.” (Claims 1–26 as provided in prompt text).
